Search
Ceruletide
go.drugbank.com/drugs/DB00403ApprovedCaerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. … It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles.
Categories: Tests for Bile Duct PatencyBenzonatate
go.drugbank.com/drugs/DB00868Approved[L11193] Although it not prone to drug misuse or abuse, benzonatate is associated with a risk for severe toxicity and overdose, especially in children.[A189513] … [A5790] Currently, benzonatate is the only non-narcotic antitussive available as a prescription drug.
Synonyms: nonaethyleneglycol monomethyl ether p-n-butylaminobenzoateMethsuximide
go.drugbank.com/drugs/DB05246ApprovedMesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.
Synonyms: N,2-Dimethyl-2-phenylsuccinimide, alpha-Methyl-alpha-phenyl N-methyl succinimideEftrenonacog alfa
go.drugbank.com/drugs/DB11608Approvedepisodes caused spontaneously or as a result of accidental or surgical trauma [FDA Label]. … Eftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B.
Polysilicone-15
go.drugbank.com/drugs/DB11271ApprovedWhen included in various other cosmetic shampoos, conditioners, or hairsprays the compound also functions as an effective photostabilizer of the product [L2796, L2797, L2799, F87, F88, F89]. … The compound is a colorless to pale yellow viscous liquid which is soluble in organic solvents of medium polarity and insoluble in water [L2796, L2797, L2799, F87, F88, F89].
Mixtures: OHUI SUN SCIENCE Perfect Sunblock Blue EX plusInebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigational[L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis
Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalIt has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Categories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexBamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalBamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179]
Categories: Experimental Unapproved Treatments for COVID-19Rosoxacin
go.drugbank.com/drugs/DB00817ApprovedRosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. … Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin,
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseLeniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45753] Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.[A258468] … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).